AZ Licensing Deal Boosts Mereo Orphan Disease Model
Executive Summary
UK group Mereo BioPharma is paying a very reasonable $5m to get its hands on AstraZeneca’s Phase II compound for the rare genetic disorder AATD.
You may also be interested in...
Timing Is Everything As Mereo Still Eyes US Listing
The London-headquartered firm believes that its efficient control of costs and strong data in support of its investigational treatments for rare respiratory, bone and endocrine diseases will attract investors across the Atlantic once it decides to refile for a listing on the Nasdaq.
Deal Watch: Neos Says ‘Thanks, No Thanks’ To Repeated PDL Offer
Daiichi teams with Glycotope on an antibody-drug conjugate for cancer, while Alector will partner with AbbVie to research antibody targets for Alzheimer’s disease.
Circassia Builds US Respiratory Presence with AstraZeneca Deal
Circassia has put memories of last year's Cat-SPIRE disappointment firmly behind it with a new deal with AstraZeneca for Tudorza and Duaklir in COPD that will allow it to concentrate on boosting its respiratory franchise.